Bgm (BGM) Short term Debt (2019 - 2025)

Bgm (BGM) posted quarterly Short term Debt of $1.6 million for Q3 2025, up 1.02% quarter-over-quarter from $1.6 million in Q1 2025.

Bgm (BGM) Short term Debt (2019 - 2025) Analysis & Trends

Bgm (BGM) has reported Short term Debt for 5 consecutive years, with $1.6 million the latest figure, recorded in Q3 2025.

In Q3 2025, Short term Debt changed N/A year-over-year to $1.6 million; the TTM figure through Sep 2025 stood at $1.6 million (changed N/A YoY), while the FY2025 annual figure was $1.6 million, changed N/A from the prior year.
Short term Debt improved to $1.6 million in Q3 2025 per BGM's latest filing, from $1.6 million in the prior quarter.
Across five years, Short term Debt topped out at $3153.0 billion in Q1 2022 and bottomed at $140578.0 in Q3 2022.
Historically, Short term Debt has averaged $630.6 billion across 3 years, with a median of $1.6 million in 2025.
On a YoY basis, Short term Debt climbed as much as 241.24% in 2023 and fell as far as 241.24% in 2023.
Bgm's Short term Debt stood at $140578.0 in 2022, then jumped by 241.24% to $479715.0 in 2023, then soared by 237.38% to $1.6 million in 2025.
Business Quant data shows BGM's Short term Debt at $1.6 million in Q3 2025, $1.6 million in Q1 2025, and $479715.0 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-
10	Bgm	30.61 Mn	20.79 Mn	-

Download Data